CoChat
Sign Up
Cited by 4Erythropoietin and Anemia TreatmentCardiovascular Function and Risk FactorsChronic Kidney Disease and Diabetes

Association of Red Blood Cell Life Span with Abnormal Changes in Cardiac Structure and Function in Non-Dialysis Patients with Chronic Kidney Disease Stages 3–5

Open access
Rao, Siyi, Zhang, Jing, Lin, Jiaqun, Wan, Jianxin, Chen, Yi·2022·Journal of Clinical Medicine
DOI 10.3390/jcm11247373PMC PMC9782058
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction: With the invention and improvement of the carbon monoxide (CO) breath test, the role of shortened red blood cell life span (RBCLS) in renal anemia, an independent risk factor for cardiovascular events in patients with chronic kidney disease (CKD), is gradually attracting attention. Considering that heart failure is the leading cause of morbidity and mortality in patients with CKD, this study investigated the correlation between the RBCLS and the cardiac structure and function in non-dialysis patients with CKD stages 3−5, aiming to provide new ideas to improve the long-term prognosis of CKD patients. Methods: One hundred thirty-three non-dialysis patients with CKD stages 3−5 were tested for RBCLS. We compared the serological data, cardiac ultrasound results, and follow-up prognosis of patients with different RBCLS. Results: As the RBCLS shortened, the patients’ blood pressure, BNP, and CRP gradually increased, most significantly in patients with an RBCLS < 50 d. Patients with an RBCLS < 50 d had substantially lower hemoglobin (Hb), hematocrit, and albumin levels than those with an RBCLS ≥ 50 d. The cardiac ultrasound results show that patients with an RBCLS < 50 d had significantly larger atrial diameters than those with an RBCLS ≥ 50 d and were associated with more severe diastolic dysfunction. Patients with an RBCLS < 50 d had a 3.06 times greater risk of combined heart failure at baseline than those with an RBCLS ≥ 70 d and a higher risk of heart failure at follow-up. CKD stage 5 patients with an RBCLS < 50 d were more likely to develop heart failure and require renal replacement therapy earlier than patients with an RBCLS ≥ 50 d. Conclusions: In non-dialysis patients with CKD stages 3−5, there is a correlation between the red blood cell life span and cardiac structure and function. The RBCLS may also impact the renal prognosis of CKD patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm11247373

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Alterations in RBC lifespan and membrane properties, as observed in chronic kidney disease, are associated with impaired nitrite reduction and reduced vascular benefits.

    “Alterations in RBC lifespan and membrane properties, as observed in chronic kidney disease, are associated with impaired nitrite reduction and reduced vascular benefits [90].”

    From Dietary Nitrate-Rich Vegetables as Natural Modulators of Health: Mechanisms and Benefits in Ageing Populations (2026) · cites this paper as [90]

    The Discussion reports that shorter red blood cell lifespan is associated with cardiac abnormalities in CKD and proposes that reduced nitric oxide may impair vasodilation. It does not link altered membrane properties or lifespan to impaired nitrite reduction; the cited nitrite-related work appears only as a reference title. No page numbers are available in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 42 · Cited by 4

Research works printed but not linked: 33

  1. [1]Hill N.R. Fatoba S.T. Oke J.L. Hirst J.A. O’Callaghan C.A. Lasserson D.S. Hobbs F.D.R. Global Prevalence of Chronic Kidney Disease—A Systematic Review and Meta-Analysis PLoS ONE 2016 11 e0158765 10.1371/journal.pone.0158765 27383068 PMC4934905 · DOI
  2. [2]Tonelli M. Muntner P. Lloyd A. Manns B.J. Klarenbach S. Pannu N. James M.T. Hemmelgarn B.R. Alberta Kidney Disease N. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study Lancet 2012 380 807 814 10.1016/S0140-6736(12)60572-8 22717317 · DOI
  3. [3]Matsushita K. Coresh J. Sang Y. Chalmers J. Fox C. Guallar E. Jafar T. Jassal S.K. Landman G.W.D. Muntner P. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data Lancet Diabetes Endocrinol. 2015 3 514 525 10.1016/S2213-8587(15)00040-6 26028594 PMC4594193 · DOI
  4. [4]Major R.W. Cheng M.R.I. Grant R.A. Shantikumar S. Xu G. Oozeerally I. Brunskill N.J. Gray L.J. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis PLoS ONE 2018 13 e0192895 10.1371/journal.pone.0192895 29561894 PMC5862400 · DOI
  5. [5]Kim-Mitsuyama S. Soejima H. Yasuda O. Node K. Jinnouchi H. Yamamoto E. Sekigami T. Ogawa H. Matsui K. Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: A subgroup analysis of the ATTEMPT-CVD randomized trial Hypertens. Res. 2019 42 883 891 10.1038/s41440-019-0210-1 30664702 · DOI
  6. [6]Roestenberg M. Hoogerwerf M.-A. Ferreira D.M. Mordmüller B. Yazdanbakhsh M. Experimental infection of human volunteers Lancet Infect. Dis. 2018 18 e312 e322 10.1016/S1473-3099(18)30177-4 29891332 · DOI
  7. [7]Zhang H.-D. Ma Y.-J. Liu Q.-F. Ye T.-Z. Meng F.-Y. Zhou Y.-W. Yu G.-P. Yang J.-P. Jiang H. Wang Q.-S. Human erythrocyte lifespan measured by Levitt’s CO breath test with newly developed automatic instrument J. Breath Res. 2018 12 036003 10.1088/1752-7163/aaacf1 29400658 · DOI
  8. [9]Chawla L.S. Herzog C.A. Costanzo M.R. Tumlin J. Kellum J.A. McCullough P.A. Ronco C. Workgroup A.X. Proposal for a Functional Classification System of Heart Failure in Patients With End-Stage Renal Disease: Proceedings of the acute dialysis quality initiative (ADQI) XI workgroup J. Am. Coll. Cardiol. 2014 63 1246 1252 10.1016/j.jacc.2014.01.020 24530671 · DOI
  9. [10]Lang R.M. Badano L.P. Mor-Avi V. Afilalo J. Armstrong A. Ernande L. Flachskampf F.A. Foster E. Goldstein S.A. Kuznetsova T. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of, Cardiovascular Imaging Eur. Hear. J.-Cardiovasc. Imaging 2016 17 412 10.1093/ehjci/jew041 25712077 · DOI
  10. [11]Fletcher A. Singh T. Syed M. Dweck M. Imaging aortic valve calcification: Significance, approach and implications Clin. Radiol. 2020 76 15 26 10.1016/j.crad.2020.04.007 32446601 · DOI
  11. [12]Wang X. Hao G. Chen L. Zhang L.F. Chen Z. Kang Y.T. Yang Y. Zheng C.Y. Zhou H.Q. Wang Z.W. Heart failure and left ventricular dysfunction in older patients with chronic kidney disease: The China Hypertension Survey (2012–2015) J. Geriatr. Cardiol. 2020 17 597 603 10.11909/j.issn.1671-5411.2020.10.001 33224178 PMC7657946 · DOI
  12. [13]Novoradovskaya N. Lee J. Yu Z.X. Ferrans V.J. Brantly M. Inhibition of intracellular degradation increases secretion of a mutant form of alpha1-antitrypsin associated with profound deficiency J. Clin. Investig. 1998 101 2693 2701 10.1172/JCI549 9637703 PMC508860 · DOI
  13. [14]Cohen R.M. Franco R.S. Khera P.K. Smith E.P. Lindsell C.J. Ciraolo P.J. Palascak M.B. Joiner C.H. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c Blood 2008 112 4284 4291 10.1182/blood-2008-04-154112 18694998 PMC2581997 · DOI
  14. [15]Mock D.M. Matthews N.I. Zhu S. Strauss R.G. Schmidt R.L. Nalbant D. Cress G.A. Widness J. Red blood cell (RBC) survival determined in humans using RBCs labeled at multiple biotin densities Transfusion 2010 51 1047 1057 10.1111/j.1537-2995.2010.02926.x 21062290 PMC3089718 · DOI
  15. [16]Farah C. Michel L.Y.M. Balligand J.-L. Nitric oxide signalling in cardiovascular health and disease Nat. Rev. Cardiol. 2018 15 292 316 10.1038/nrcardio.2017.224 29388567 · DOI · Paper page
  16. [17]Kuhn V. Diederich L. Keller T.C.S. Kramer C.M. Lückstädt W. Panknin C. Suvorava T. Isakson B.E. Kelm M. Cortese-Krott M.M. Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia Antioxid. Redox Signal. 2017 26 718 742 10.1089/ars.2016.6954 27889956 PMC5421513 · DOI · Paper page
  17. [20]Rifkind J.M. Mohanty J.G. Nagababu E. Salgado M.T. Cao Z. Potential Modulation of Vascular Function by Nitric Oxide and Reactive Oxygen Species Released from Erythrocytes Front. Physiol. 2018 9 690 10.3389/fphys.2018.00690 29930515 PMC5999795 · DOI
  18. [21]Zhou Z. Mahdi A. Tratsiakovich Y. Zahorán S. Kövamees O. Nordin F. Uribe Gonzalez A.E. Alvarsson M. Östenson C.-G. Andersson D.C. Erythrocytes from Patients with Type 2 Diabetes Induce Endothelial Dysfunction Via Arginase I J. Am. Coll. Cardiol. 2018 72 769 780 10.1016/j.jacc.2018.05.052 30092954 · DOI
  19. [22]Yang J. Zheng X. Mahdi A. Zhou Z. Tratsiakovich Y. Jiao T. Kiss A. Kövamees O. Alvarsson M. Catrina S.-B. Red Blood Cells in Type 2 Diabetes Impair Cardiac Post-Ischemic Recovery through an Arginase-Dependent Modulation of Nitric Oxide Synthase and Reactive Oxygen Species JACC: Basic Transl. Sci. 2018 3 450 463 10.1016/j.jacbts.2018.03.006 30175269 PMC6115643 · DOI
  20. [23]Wautier J.-L. Wautier M.-P. Molecular basis of erythrocyte adhesion to endothelial cells in diseases Clin. Hemorheol. Microcirc. 2013 53 11 21 10.3233/CH-2012-1572 22941965 · DOI
  21. [24]Pinlaor S. Onsurathum S. Boonmars T. Pinlaor P. Hongsrichan N. Chaidee A. Haonon O. Limviroj W. Tesana S. Kaewkes S. Distribution and Abundance of Opisthorchis viverrini Metacercariae in Cyprinid Fish in Northeastern Thailand Korean J. Parasitol. 2013 51 703 710 10.3347/kjp.2013.51.6.703 24516277 PMC3916461 · DOI
  22. [25]Parikh N.I. Hwang S.-J. Larson M. Meigs J.B. Levy D. Fox C.S. Cardiovascular Disease Risk Factors in Chronic Kidney Disease: Overall burden and rates of treatment and control Arch. Intern. Med. 2006 166 1884 1891 10.1001/archinte.166.17.1884 17000946 · DOI
  23. [26]Manjunath G. Tighiouart H. Ibrahim H. MacLeod B. Salem D.N. Griffith J.L. Coresh J. Levey A.S. Sarnak M.J. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community J. Am. Coll. Cardiol. 2002 41 47 55 10.1016/S0735-1097(02)02663-3 12570944 · DOI
  24. [27]Hickson L.J. Negrotto S.M. Onuigbo M. Scott C.G. Rule A.D. Norby S.M. Albright R.C. Casey E.T. Dillon J.J. Pellikka P.A. Echocardiography Criteria for Structural Heart Disease in Patients with End-Stage Renal Disease Initiating Hemodialysis J. Am. Coll. Cardiol. 2016 67 1173 1182 10.1016/j.jacc.2015.12.052 26965538 PMC4788810 · DOI
  25. [28]Pluta A. Stróżecki P. Krintus M. Odrowąż-Sypniewska G. Manitius J. Left ventricular remodeling and arterial remodeling in patients with chronic kidney disease stage 1–3 Ren. Fail. 2015 37 1105 1110 10.3109/0886022X.2015.1061669 26156686 · DOI
  26. [29]Pernow J. Jung C. Arginase as a potential target in the treatment of cardiovascular disease: Reversal of arginine steal? Cardiovasc. Res. 2013 98 334 343 10.1093/cvr/cvt036 23417041 · DOI
  27. [30]Kövamees O. Shemyakin A. Checa A. Wheelock C.E. O Lundberg J. Östenson C.-G. Pernow J. Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes mellitus J. Clin. Endocrinol. Metab. 2016 101 3952 3958 10.1210/jc.2016-2007 27399350 · DOI
  28. [32]Kottgen A. Russell S.D. Loehr L. Crainiceanu C.M. Rosamond W.D. Chang P.P. Chambless L.E. Coresh J. Reduced Kidney Function as a Risk Factor for Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study J. Am. Soc. Nephrol. 2007 18 1307 1315 10.1681/ASN.2006101159 17344421 · DOI
  29. [33]Ronksley P.E. Tonelli M. Manns B.J. Weaver R.G. Thomas C.M. MacRae J. Ravani P. Quinn R.R. James M.T. Lewanczuk R. Emergency Department Use among Patients with CKD: A Population-Based Analysis Clin. J. Am. Soc. Nephrol. 2017 12 304 314 10.2215/CJN.06280616 28119410 PMC5293336 · DOI
  30. [34]Porter A.C. Lash J.P. Xie D. Pan Q. DeLuca J. Kanthety R. Kusek J.W. Lora C.M. Nessel L. Ricardo A.C. Predictors and Outcomes of Health–Related Quality of Life in Adults with CKD Clin. J. Am. Soc. Nephrol. 2016 11 1154 1162 10.2215/CJN.09990915 27246012 PMC4934840 · DOI
  31. [35]Afsar B. Rossignol P. van Heerebeek L. Paulus W.J. Damman K. Heymans S. van Empel V. Sag A. Maisel A. Kanbay M. Heart failure with preserved ejection fraction: A nephrologist-directed primer Hear. Fail. Rev. 2017 22 765 773 10.1007/s10741-017-9619-2 28497230 · DOI
  32. [36]Diaz-Ricart M. Torramadé-Moix S. Pascual G. Palomo M. Moreno-Castaño A.B. Martinez-Sanchez J. Vera M. Cases A. Escolar G. Endothelial Damage, Inflammation and Immunity in Chronic Kidney Disease Toxins 2020 12 361 10.3390/toxins12060361 32492843 PMC7354562 · DOI
  33. [37]Nohara N. Io H. Matsumoto M. Furukawa M. Okumura K. Nakata J. Shimizu Y. Horikoshi S. Tomino Y. Predictive factors associated with increased progression to dialysis in early chronic kidney disease (stage 1–3) patients Clin. Exp. Nephrol. 2015 20 740 747 10.1007/s10157-015-1210-3 26707759 · DOI

Authors
Rao, S., Zhang, J., Lin, J., Wan, J., & Chen, Y.
Affiliations
Fujian Medical University (CN)
Corresponding author
  • Wan, Jianxin
  • Chen, Yi
ORCID
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2022-12-12
Volume
11
Issue
24
Pages
7373
ISSN
2077-0383 (ISSN-L)
DOI
10.3390/jcm11247373
PMC
PMC9782058
OpenAlex
W4312127050
Cited by
4
References
42
Citations by year
2026: 1 · 2025: 1 · 2024: 1
FWCI
0.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Fujian Provincial Science and Technology Plan Project (2021Y2005)
Topics
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
red blood cell lifespan, chronic kidney disease, heart failure, cardiac structure and function, diastolic dysfunction, atrial enlargement, carbon monoxide breath test, anemia of chronic kidney disease, cardiovascular risk, non-dialysis patients, prognosis, renal replacement therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review